HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NGOs To Assert COVID-Unsafe Cosmetic Ingredients In Next US Legislative Reform Push

Executive Summary

The Campaign for Safe Cosmetics, powered by Breast Cancer Prevention Partners and the Environmental Working Group, intends to present the 117th Congress with links between cosmetic ingredients and increased COVID susceptibility as part of its push for tighter cosmetics industry oversight.

You may also be interested in...



US Senate Wants PFAS Banned From Cosmetics. Should FDA Have A Say?

Per- and polyfluoroalkyl substances are unpopular, sure. But there are thousands of PFAS with dissimilar safety profiles that merit US FDA review ahead of a blanket ban in cosmetic products, industry says.

US FDA Addresses PFAS In Cosmetics, Aiming To Close Data Gaps

Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.

Trump Signs US Appropriations-COVID Relief Bill With Cosmetics, Cannabis, Dietary Provisions

The Consolidated Appropriations Act, H.R. 133, includes $900bn in unemployment relief to COVID victims as well as regular federal appropriations to avoid a looming government shutdown. US FDA provisions include cosmetics and nutrition industry mentions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel